September 2008 Briefing - HIV & AIDS

Here are what the editors at HealthDay consider to be the most important developments in HIV & AIDS for September 2008. This roundup includes the latest research news from journal articles, as well as the FDA approvals and regulatory changes that are the most likely to affect clinical practice.

News Media Under-Report Drug Company Funding of Research

TUESDAY, Sept. 30 (HealthDay News) -- Reports on medication research published in general news media often fail to disclose that the research received pharmaceutical company funding and frequently refer to drugs by brand name rather than using the generic name, according to an article published in the Oct. 1 issue of the Journal of the American Medical Association.

Abstract
Full Text (subscription or payment may be required)

HIV Prevalence High Among Injection Drug Users

WEDNESDAY, Sept. 24 (HealthDay News) -- Although the data is limited, injection drug use occurs in most countries and the prevalence of HIV among injection drug users is over 40 percent in some cases, according to a report published online Sept. 24 in The Lancet.

Abstract
Full Text (subscription or payment may be required)
Editorial

Monitoring Strategy Cost-Effective in HIV Treatment

WEDNESDAY, Sept. 24 (HealthDay News) -- Monitoring CD4 counts in people with HIV in resource-limited countries can considerably improve life expectancy and reduce total costs compared to the usual symptom-based approaches, according to research published in the Sept. 22 issue of the Archives of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

No Change to 2009 Part B Medicare Premium

MONDAY, Sept. 22 (HealthDay News) -- There will be no change to the Part B Standard Medicare premium in 2009 compared with 2008. This is the first time since 2000 that the premium has not risen over the prior year, according to an announcement by the Department of Health and Human Services' Centers for Medicare & Medicaid Services (CMS).

More Information

Antibiotic Resistance Has Become a Global Pandemic

FRIDAY, Sept. 19 (HealthDay News) -- A concerted international and national response, behavior change by consumers and providers, and the development of antibacterial agents are all urgently needed to tackle the global problem of rapidly increasing antibiotic resistance, according to an article published online Sept. 18 in BMJ.

Abstract
Full Text (subscription or payment may be required)

Gay Men Account for 72 Percent of New HIV Infections

FRIDAY, Sept. 12 (HealthDay News) -- Men who have sex with men accounted for 72 percent of new HIV infections in the United States in 2006, and blacks and Hispanics were disproportionately represented, according to study findings published in the Sept. 12 issue of the U.S. Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report.

More Information

Chronic Disease Is Heavy Burden in Developing World

FRIDAY, Sept. 12 (HealthDay News) -- Although many countries have made significant progress in reducing mortality, the burden of chronic and non-communicable disease remains heavy and requires integrated strategies to tackle it, according to three papers published in the Sept. 13 issue of The Lancet, which has a special focus on the legacy of the 1978 International Conference on Primary Health Care in Alma-Ata.

Abstract - Tollman
Full Text (subscription or payment may be required)
Abstract - Lawn
Full Text (subscription or payment may be required)
Abstract - Beaglehole
Full Text (subscription or payment may be required)
Editorial

HIV Infection Linked to More Fractures

FRIDAY, Sept. 5 (HealthDay News) -- HIV-infected patients have a higher prevalence of fracture at multiple sites compared with non-infected individuals, according to research published in the September issue of the Journal of Clinical Endocrinology & Metabolism.

Abstract
Full Text

Episodic HIV Antiretroviral Therapy Seen As Hazardous

THURSDAY, Sept. 4 (HealthDay News) -- Because HIV-positive patients who are placed on episodic antiretroviral therapy still have an excess risk of opportunistic disease or death after continuous therapy is reinstated, episodic therapy should be avoided, according to research published in the Sept. 2 issue of the Annals of Internal Medicine.

Abstract
Full Text (subscription or payment may be required)

ACOG: Clinicians Must Address Non-Coital Sex Risks

WEDNESDAY, Sept. 3 (HealthDay News) -- Because non-coital sex including mutual masturbation, oral sex and anal sex can increase the high risk of sexually transmitted diseases, it is important that clinicians ask direct questions about their patients' non-coital sexual activity and provide risk reduction counseling, according to an American College of Obstetricians and Gynecologists Committee Opinion published in the September issue of Obstetrics & Gynecology.

Full Text (subscription or payment may be required)

Related Stories

No stories found.
logo
www.healthday.com